Sign Up
OverviewAPI
Ethris GmbH has initiated the first-in-human dosing of ETH47, a lead candidate for the treatment of virus-induced asthma, in a Phase 1 study. The program has the potential to address pandemic preparedness against influenza and SARS-CoV-2. ETH47 aims to induce mucosal innate immune responses at viral entry sites with a virus- and mutation-independent mode of action. The Phase 1 clinical trial will evaluate safety, tolerability, pharmacokinetics, and target engagement, with funding from Bayern Innovativ and enrolling 88 healthy participants at a trial site in the UK.

Ask a question